aBLA Filing Intelligence & Biosimilar Opportunity

Nemluvio

Nemolizumab-Ilto

Immunomodulators

Prefilled Pen For Injection

Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.

Approval Date

12-Aug-24

Data Exclusivity Expiry

12-Aug-28

Market Exclusivity Expiry

12-Aug-36

Commercial snapshot

Market performance & projections

Revenue ($M)

452

CAGR (%)

57.88%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1,115

2027

1,671

2028

2,265

2029

2,808

2030

3,279

2031

3,743

2032

4,191

Molecule profile

Details & specifications

Molecule

Nemolizumab-Ilto

Innovator

CHUGAI PHARMACEUTICAL CO., LTD.

Dosage Form

Prefilled Pen For Injection

Strength

30 mg

Therapeutic Category

Immunomodulators

Usage

To treat prurigo nodularis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets